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Abstract MEF2C is a transcription factor expressed in neural
lineages. After transient transfection, the MEF2 family of
factors can act synergistically with the neural-specific transcrip-
tion factor, MASH-1, and activate exogenous neural-specific
promoters. To determine whether MEF2C is capable of
modulating endogenous gene expression, P19 cell lines were
analyzed that overexpressed MEF2C, termed P19[MEF2C]
cells. Here we show that P19[MEF2C] cells differentiate into
neurons when aggregated with ME2SO. MEF2C-induced
neurons expressed neurofilament protein, the nuclear antigen
NeuN, as well as MASH-1. Our results indicate that MEF2C
can directly or indirectly activate the expression of MASH-1,
leading to neurogenesis.
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1. Introduction
The four vertebrate MEF2 family members, MEF2A^D
[1,2], contain a conserved MADS box/MEF2 domain at their
N-termini. This domain mediates protein^protein interactions
as well as DNA binding to an AT-rich MEF2 binding site.
The MEF2 family of transcription factors has been implicated
in controlling tissue-speci¢c gene expression in skeletal, car-
diac, and smooth muscle cells [2,3] as well as in brain and
neuronal cells [4^10].
An essential role for D-MEF2 in the development of car-
diac, skeletal, and smooth muscle has been demonstrated by
the de¢ciency of these tissues in Drosophila lacking the single
D-mef2 gene [11^13]. During murine somitogenesis, MEF2C
is the ¢rst MEF2 factor to be expressed in the somite on day
9, just after expression of myogenin [14,15]. In mammalian
systems, the analysis of mice lacking MEF2 family members
is complicated by possible functional redundancy. For exam-
ple, mice lacking MEF2C die around embryonic day 10 due to
a defect in cardiac looping while mice lacking MEF2B are
viable and develop normally.
In order to determine if MEF2 factors are capable of acti-
vating endogenous tissue-speci¢c gene expression in mamma-
lian systems, we have analyzed the ability of MEF2C to
change the developmental potential of murine P19 embryonal
carcinoma cells. These cells have a stable diploid karyotype
and are pluripotent. Cellular aggregation in the presence of
drugs induces di¡erentiation that emulates the biochemical
and morphological events of early embryonic development
[16,17]. Aggregation of P19 cells with retinoic acid results in
the development of various neuroectodermal derivatives, in-
cluding neurons, astrocytes, and glia [17,18]. P19-derived neu-
rons express MEF2C [4] and the neurogenic basic helix-loop-
helix (bHLH) transcription factor MASH-1 [19]. These two
factors can physically interact to synergistically activate tran-
scription. When stably expressed in P19 cells, a dominant-
negative MEF2C was able to suppress the expression of the
N-methyl-D-aspartate receptor subunit 1 in cells treated with
retinoic acid, indicating that MEF2C activity is essential for
the expression of at least one neuron-speci¢c gene [10]. Fur-
thermore, the transient expression of neural bHLH proteins,
including MASH-1, has been shown to convert monolayer
cultures of P19 cells into neurons [20].
The approach of stably overexpressing transcription factors
in P19 cells has yielded important information about the func-
tion and regulation of these factors [21]. For example, P19
cells overexpressing either GATA-4 [22] or MyoD [23] di¡er-
entiate into cardiac muscle or skeletal muscle, respectively,
when aggregated in the absence of ME2SO. Using this ap-
proach, we have shown recently that MEF2C and Nkx2-5
activate each other’s expression and induce cardiomyogenesis
in P19 cells [24]. Furthermore, MEF2C and myogenin activate
each other’s expression and induce skeletal myogenesis [25].
Here we show that MEF2C can induce neurogenesis when
overexpressed in P19 cells.
2. Materials and methods
2.1. Tissue culture
Routine culturing of P19 cells and the isolation of P19 cells over-
expressing MEF2C, termed P19[MEF2C] cells, have been described
previously [24]. Each of the three high expressing P19[MEF2C] cell
lines behaved similarly and all experiments reported were performed
at least twice with at least two of these cell lines, with similar results.
Di¡erentiation was initiated by plating 5U105 cells into 60 mm
bacterial dishes in the presence of 0.8% ME2SO. Cells were cultured
as aggregates for 4 days and then plated in tissue culture dishes and
harvested for RNA or ¢xed for immuno£uorescence at the time in-
dicated.
2.2. Immuno£uorescence
P19 and P19[MEF2C] cells were plated on day 4 of di¡erentiation
onto gelatin-coated coverslips. For identifying the neuro¢lament 68
kDa protein [26], cells were ¢xed in methanol at 320‡C and reacted
with antibody as described [23]. For identifying NeuN and MASH-1,
cells were ¢xed for 1 h at room temperature with Lana’s ¢xative (4%
paraformaldehyde, 14% v/v saturated picric acid, 125 mM sodium
phosphate) followed by preblocking in 1% goat serum, 0.1% NP40
in phosphate-bu¡ered saline (PBS) for 15 min at room temperature.
Cells were then incubated overnight at 4‡C with 50 Wl of the mono-
clonal antibody supernatants against NeuN, A60 [27], and MASH-1
[19]. After three 5 min washes in PBS, cells were incubated for 30 min
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 4 3 8 - 1
*Corresponding author. Fax: (1)-519-661 3175.
E-mail: skerjanc@julian.uwo.ca
FEBS 23574 14-4-00
FEBS 23574 FEBS Letters 472 (2000) 53^56
in 50 Wl of PBS with 1 Wl of goat anti-mouse IgG(H+L) Cy3-linked
antibody (Jackson Immunoresearch Laboratories, PA). Immuno£uor-
escence was visualized with a Zeiss Axioskop microscope, images were
captured with a Sony 3CCD color video camera, processed using
Northern Exposure, Adobe Photoshop, and Corel Draw software,
and printed with a dye sublimation phaser 450 Tektronic printer.
3. Results and discussion
P19 cells di¡erentiate into neuroectodermal lineages when
aggregated with retinoic acid but not when aggregated with
ME2SO or in the absence of retinoic acid [16]. To examine
whether MEF2C can activate the expression of endogenous
genes in the neuronal pathway, P19[MEF2C] cells were aggre-
gated in the presence and absence of ME2SO. Immuno£uor-
escence was performed with an anti-neuro¢lament antibody,
NF68 [17,23], and with an anti-NeuN antibody [27]. Neurons
were observed in P19[MEF2C] cultures that were aggregated
with ME2SO, as shown by the expression of neuro¢lament
protein (Fig. 1B) and by the nuclear expression of NeuN
(Fig. 1D). As expected, control P19 cells did not express neu-
ron-speci¢c proteins when aggregated with ME2SO (Fig.
1A,C). The neurons appeared to have a similar morphology
when compared to neurons induced by retinoic acid [17].
In order to quantify MEF2C-induced neurogenesis, the
numbers of neurons were counted in P19 and P19[MEF2C]
cultures treated with and without ME2SO. P19[MEF2C] cells
Fig. 1. MEF2C induces the expression of neuron-speci¢c proteins. P19 (A, C) and P19[MEF2C] (B, D) cells were di¡erentiated in the presence
of ME2SO and ¢xed on day 9. Cells were stained with an anti-neuro¢lament (NF68) antibody (A, B) [26] or an anti-NeuN antibody (C, D)
[27]. Magni¢cation 35U.
Table 1
Comparison of the requirements and extent of di¡erentiation for various P19 cell lines
P19[MEF2C] P19[MyoD] P19
Cell types produced skeletal cardiac neurons skeletal skeletal cardiac neurons
Drug requirement DMSO None DMSO None DMSO DMSO retinoic acid
Extent of di¡erentiation (%) V5 V2 5^9 V30 6 5 V15 V75
Time course (days) 9 6 6 6 9 6 6
Reference [25] [24] this work [23] [17] [17] [16]
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di¡erentiated into neurons as early as day 6 in the presence of
ME2SO (Fig. 2) and they represented 5^9% of total cells. No
neurons were detected in cultures treated without ME2SO. In
addition to the presence of neurons on day 6, P19[MEF2C]
cultures treated with dimethyl sulfoxide (DMSO) also con-
tained V15% of DMSO-induced cardiac muscle [25], V5%
skeletal muscle precursors [25], V10% smooth muscle
(smooth muscle actin-positive; data not shown), and V5%
endoderm (cytokeratin-positive; data not shown). Cardiac
muscle, smooth muscle, and endoderm are present in control
cultures treated with DMSO.
We have previously reported that MEF2C induces cardio-
myogenesis [24] and skeletal myogenesis [25] in aggregated
P19 cells. It seems that the initiation of skeletal myogenesis,
neurogenesis, and cardiomyogenesis by MEF2C is an all-or-
none event and requires speci¢c aggregation conditions (sum-
marized in Table 1). There was no indication of a mixed
phenotype between the three cell types produced. For exam-
ple, neuro¢lament protein was not found in cells with a skel-
etal or cardiac myocyte morphology and myogenin was not
found in cells with a neuronal morphology. Therefore,
MEF2C activity must be carefully regulated by lineage-re-
stricted factors to ensure that the correct combination of
genes is activated in order to de¢ne a speci¢c developmental
pathway.
Since MASH-1 is known to act cooperatively with MEF2
factors, to be expressed during P19 cell di¡erentiation into
neurons [4,7,19], and to convert P19 cells into neurons [20],
we examined aggregated P19[MEF2C] cultures for the pres-
ence of MASH-1. P19[MEF2C] cells expressed MASH-1 after
di¡erentiation in the presence of ME2SO (Fig. 3A), whereas
P19 control-transfected cells did not (Fig. 3B).
We propose a working model for the regulation of MEF2C
activity in P19 cells that extends previous models of MEF2C
function [2,28]. In this model, di¡erent lineage-restricted fac-
tors are expressed in a subset of P19 cells during cellular
aggregation, with a speci¢c time course and drug requirement.
These factors regulate the activity of MEF2C to initiate the
expression of tissue-restricted factors, such as MASH-1 in the
neuronal development pathway, MyoD and myogenin in the
skeletal muscle development pathway [25], and Nkx2-5 and
GATA-4 in the cardiac muscle development pathway [24].
Finally, as proposed previously, these tissue-restricted factors
may act cooperatively with MEF2C in activating the expres-
sion of neuron-speci¢c [4,7], skeletal muscle-speci¢c [29^31],
and cardiac muscle-speci¢c genes [32].
The putative lineage-restricted factors may be other tran-
scription factors, kinases, or phosphatases. MEF2C can be
regulated by phosphorylation events due to interactions with
casein kinase II [33], mitogen-activated protein kinase p38
[34], and Erk5/BMK [35]. These factors are candidates for
regulating MEF2C-induced skeletal myogenesis, neurogenesis,
and cardiogenesis.
The ability of MEF2C to initiate the development of multi-
ple cell types in di¡erentiating P19 cells is distinct from the
regulation of gene expression observed with other transcrip-
tion factors in P19 cells, such as Nkx2-5 [24], MyoD [23],
myogenin [25], and GATA-4 [22]. Nkx2-5, GATA-4, MyoD,
and myogenin trigger the development of one cell type, rep-
resenting a large proportion (s 10%) of the culture, and ex-
hibit no ME2SO requirement. In comparison, MEF2C indu-
ces the development of multiple cell types, representing small
percentages (6 10%) of the cells, and requires ME2SO for
myogenesis and neurogenesis. Consequently, it would appear
that Nkx2-5, GATA-4, MyoD, and myogenin are regulated
by factors present in a large proportion of cells in the culture
and are expressed in a ME2SO-independent fashion during
Fig. 3. MEF2C activates the expression of MASH-1. P19[MEF2C] (A) and P19 (B) cells were di¡erentiated in the presence of ME2SO and
¢xed on day 9. Cells were stained with an anti-MASH-1 antibody. Magni¢cation 70U.
Fig. 2. MEF2C induces neuronal development by day 6 after cellu-
lar aggregation in the presence of ME2SO. The total numbers of
cells expressing NeuN were counted in cultures of P19 and
P19[MEF2C] cells which had been aggregated in the presence or ab-
sence of DMSO and ¢xed on day 6 or day 9. These numbers were
averaged and depicted graphically. Error bars represent S.E.M.
(n = 3).
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cellular aggregation. In comparison, factors that regulate
MEF2C activity would be present in a small proportion of
the cells and their expression would be dependent upon the
presence or absence of ME2SO during the aggregation step.
Since MEF2C is known to bind to neuron-speci¢c pro-
moters, it is logical to assume that MEF2C is functioning in
this manner in P19 cells. However, it is possible that the
observed neurogenesis is due to an indirect e¡ect of overex-
pression of MEF2C, without any speci¢c e¡ect. For example,
MEF2C could be functioning by a ‘squelching’ mechanism by
binding a cofactor or by derepressing gene expression. Alter-
natively, MEF2C could be enhancing the spontaneous di¡er-
entiation of P19 cells.
In summary, MEF2C initiates neurogenesis in P19 cells
aggregated with ME2SO. This ¢nding is consistent with the
location of MEF2C during the development of the embryo
since MEF2C is expressed in the developing brain [2]. These
results are also consistent with the known activities of
MEF2C since, in transient transfection experiments, MEF2C
activates the promoters of neuronal-speci¢c genes [10]. Our
¢ndings extend these observations to show that MEF2C ex-
pression can result in the activation of endogenous genes in-
cluding the neuronal transcription factor MASH-1, and neu-
ron-speci¢c proteins such as NeuN and neuro¢lament,
resulting in neurogenesis. Therefore, the P19 cell system pro-
vides a useful tool for examining the ability of transcription
factors to initiate cellular di¡erentiation and for subsequent
analysis of the mechanism(s) involved. Aggregated P19 cells
provide the transfected gene of interest with a heterogeneous
population of cells, which in turn provides the appropriate
regulatory proteins and/or chromatin structure to allow for
the activation of function of the gene of interest.
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